Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial (Q84543964)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 November 2011

Language	Label	Description	Also known as
English	Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial	scientific article published on 01 November 2011

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

0 references

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Dawn M Torres

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Frances J Jones

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Janet C Shaw

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Christopher D Williams

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

John A Ward

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Stephen A Harrison

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

0 references

publication date

1 November 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

54

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1631-1639

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Lifestyle modification as the primary treatment of NASH.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Metformin in the treatment of patients with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Revisiting the rosiglitazone story--lessons learned

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.24558

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84543964&oldid=2128059612"